Immunoglobulin A vasculitis associated with inflammatory bowel disease: a retrospective cohort study
AffiliationUniv Arizona, Div Rheumatol, Arthrit Ctr
MetadataShow full item record
PublisherTAYLOR & FRANCIS LTD
CitationM Villatoro-Villar, CS Crowson, KJ Warrington, A Makol & MJ Koster (2020) Immunoglobulin A vasculitis associated with inflammatory bowel disease: a retrospective cohort study, Scandinavian Journal of Rheumatology, DOI: 10.1080/03009742.2020.1732460
RightsCopyright © 2020 Informa UK Limited
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractObjective To describe the baseline characteristics and outcome of a series of patients with inflammatory bowel disease (IBD) and immunoglobulin A vasculitis (IgAV). Method Patients with biopsy-proven IgAV with IBD were identified retrospectively. Data were abstracted from direct medical chart review. Each IBD-IgAV case was matched to two controls with IgAV but without IBD. Results Nine patients were identified (seven Crohn's disease, two ulcerative colitis). Mean length of time between IBD diagnosis and IgAV onset was 17.3 +/- 19.9 years. For patients on biologic treatment for IBD, mean length of time between biologic initiation and IgAV onset was 3.3 +/- 3.8 years. Active IBD at IgAV onset was present in 56%. Tumour necrosis factor inhibitors (TNFi) were used for IBD in 89%. At IgAV onset, six patients were on treatment with TNFi; one subsequently discontinued, two switched to another TNFi, and three continued. At the last follow-up, three of five patients who remained on TNFi had full resolution of IgAV despite ongoing TNFi use. No differences were seen between cases with IBD IgAV and matched non-IBD-IgAV controls regarding development of end-stage renal disease, resolution of haematuria or proteinuria, and time to complete IgAV response. Conclusion Baseline characteristics and outcomes of patients with IBD-IgAV are similar to those with IgAV without IBD. Development of IgAV is not limited to patients with clinically active IBD. Whether TNFi use is related to the pathogenesis of IgAV in some patients with IBD remains unclear. Further research into pathophysiological connections between IBD and IgAV is needed.
Note12 month embargo; published online: 27 May 2020
VersionFinal accepted manuscript
- Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
- Authors: Buckley LH, Xiao R, Perman MJ, Grossman AB, Weiss PF
- Issue date: 2021 Feb
- Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data.
- Authors: Tracy A, Subramanian A, Adderley NJ, Cockwell P, Ferro C, Ball S, Harper L, Nirantharakumar K
- Issue date: 2019 Feb
- The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
- Authors: Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, Bernstein CN, Bitton A, Nguyen GC, Lee K, Cooke-Lauder J, Murthy SK
- Issue date: 2019 Feb
- Clinical Characteristics of Biopsy-Proven IgA Vasculitis in Children and Adults: A Retrospective Cohort Study.
- Authors: Villatoro-Villar M, Crowson CS, Warrington KJ, Makol A, Ytterberg SR, Koster MJ
- Issue date: 2019 Sep
- Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
- Authors: Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, Bensen R, Limketkai BN, Keyashian K, Kin C
- Issue date: 2018 Aug